A GLOBAL, PATIENT-LED EFFORT TO MEASURE AND IMPROVE ECZEMA CARE AROUND THE WORLD

First of its Kind Collaboration Uses Data-Driven Approach to Evaluate and Compare Health Systems in 13 Countries

bruno-nascimento-eo11MS0FSnk-unsplash.jpg

Led by patients, driven by data

Thirteen patient organizations from thirteen countries have joined together to form the Global Patient Initiative to Improve Eczema Care (GPIIEC). The initiative is a global collaboration to establish a common “yardstick” to assess the responsiveness of health systems to the needs of patients and their caregivers. This GPIIEC identified the elements of health care provision that matter most to patients and caregivers and developed indicators with which to measure them across thirteen developed nations (Argentina, Australia, Brazil, Canada, Denmark, France, Germany, Italy, Kenya, Portugal, Spain, United States, and the United Kingdom).

Dashboard_Photo-sm.jpg

Global Measure Dashboard

The measure dashboard selected by the GPIIEC includes 7 domains related to the experience of living with eczema and the provision of medical care:

  1. Treatment Satisfaction

  2. Medical Care Delivery

  3. Control of Symptoms

  4. Burden of Illness

  5. Patient Education and Training

  6. Quality/Safety

  7. Access to Specialists and Treatments

Within each domain, the GPIIEC selected 1-2 measures that were developed using primary survey data or secondary data sources from each country of interest: Argentina, Australia, Brazil, Canada, Denmark, France, Germany, Italy, Kenya, Portugal, Spain, United States, and the United Kingdom.


 

“We need patient-centered measures for eczema, similar to those that exist for other chronic diseases, so that we can assess progress and chart a path towards improvement.”

– Melanie Funk, Managing Director with Eczema Support Australia


High Burden and Unmet Medical Needs Among Patients with Eczema and Their Caregiver in 13 Developed Countries

 

Findings from a comprehensive literature review

The literature scan reviews burden and satisfaction with healthcare and treatments across thirteen countries representing a cross-section of developed nations with disparate health care systems.

The global initiative is supported with funding from Leo Pharma and Sanofi and Regeneron.